Last SFr.29.20 CHF
Change Today -0.45 / -1.52%
Volume 0.0
PFE On Other Exchanges
New York
SIX Swiss Ex
Sao Paulo
As of 11:43 AM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

pfizer inc (PFE) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/13/15 - SFr.34.00
52 Week Low
08/8/14 - SFr.25.40
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for PFIZER INC (PFE)

pfizer inc (PFE) Details

Pfizer Inc. discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines, and various consumer healthcare products. The company’s Primary Care segment offers prescription pharmaceutical products primarily prescribed by primary-care physicians for various therapeutic and disease areas comprising Alzheimer’s disease, cardiovascular, erectile dysfunction, genitourinary, major depressive disorder, pain, respiratory, and smoking cessation. Its Specialty Care and Oncology segment provides prescription pharmaceutical products for anti-infectives, endocrine disorders, hemophilia, inflammation, ophthalmology, pulmonary arterial hypertension, specialty neuroscience, and vaccines, as well as oncology and oncology-related illnesses. The company’s Established Products and Emerging Markets segment offers prescription pharmaceutical products that had lost patent protection or marketing exclusivity in certain countries and/or regions, as well as sold in emerging markets, including Asia, Latin America, the Middle East, Eastern Europe, Africa, Turkey, and Central Europe. Its Consumer Healthcare segment provides non-prescription products in a range of therapeutic categories, such as dietary supplements, pain management, respiratory, and personal care. The company also offers Lyrica, the Prevnar family of products, Enbrel, Celebrex, Lipitor, Viagra, Zyvox, Norvasc, Sutent, and the Premarin family of products; and consumer healthcare products under the Advil, Caltrate, Centrum, ChapStick, Emergen-C, Preparation H, and Robitussin brands. It serves wholesalers, distributors, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, and grocery and convenience stores. It has strategic alliance with CliniWorks (Israel) Ltd.; and strategic collaboration with iTeos Therapeutics SA. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Founded in 1849

pfizer inc (PFE) Top Compensated Officers

Chairman, Chief Executive Officer and Chairma...
Total Annual Compensation: $1.8M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $1.2M
President of Worldwide Research and Developme...
Total Annual Compensation: $1.1M
Group President of Global Innovative Pharma B...
Total Annual Compensation: $926.3K
Group President of Global Established Pharma ...
Total Annual Compensation: $810.1K
Compensation as of Fiscal Year 2013.

pfizer inc (PFE) Key Developments

Pfizer (US) to Increase Production Capacity in Itapevi, Brazil

Pfizer (US) has invested USD 27 million in increasing production capacity in Itapevi, Brazil. This investment will increase the US firm's production capacity in Itapevi from 20 million units per year to 48 million units, through the improvement of its technology and processes, with full capacity expected to be reached in 2016. Additionally, the US company is also planning to add approximately 20 innovative medicines to its portfolio produced in Brazil.

Pfizer Declares Dividend for the First Quarter of 2015 Payable on March 3, 2015

Pfizer announced that the Board of Directors declared first-quarter 2015 dividend of 28-cent on the company's common stock, payable on March 3, 2015, to shareholders of record at the close of business on February 6, 2015. This represents an increase of 8% in the quarterly dividend per share, compared to 26 cents per share in first-quarter 2014.

Pfizer Inc. Announces Unaudited Consolidated Earnings Results for Fourth Quarter and Full Year Ended December 31, 2014; Provides Earnings Guidance for 2015

Pfizer Inc. announced unaudited consolidated earnings results for fourth quarter and full year ended December 31, 2014. For the quarter, the company reported revenues of $13,118 million against $13,558 million a year ago. Adjusted income was $3,441 million against $3,686 million a year ago. Adjusted diluted EPS were $0.54 against $0.56 a year ago. Reported net income was $1,228 million against $2,568 million a year ago. Reported diluted EPS were $0.19 against $0.39 a year ago. Reported revenues decreased $440 million, or 3%, which reflects slight operational growth of $9 million, and the unfavorable impact of foreign exchange of $449 million, or 3%. Operational growth in developed markets was driven by the performance of certain key products, including Lyrica, Prevnar and Eliquis, as well as Xeljanz primarily in the U.S. Additionally, revenues in emerging markets increased 7% operationally, including strong operational growth from Lipitor, primarily in China, as well as Prevenar and Enbrel. This operational growth was offset primarily by the loss of exclusivity and subsequent multi-source generic competition for Celebrex in the U.S., the expiration of the co-promotion term of the collaboration agreement for Enbrel in the U.S. and Canada, the termination of the Spiriva collaboration in certain countries as well as by other product losses of exclusivity in certain markets. For the full year, the company reported revenues of $49,605 million against $51,584 million a year ago. Adjusted income was $14,530 million against $15,288 million a year ago. Adjusted diluted EPS were $2.26 against $2.22 a year ago. Reported net income was $9,135 million against $22,093 million a year ago. Reported diluted EPS were $1.42 against $3.19 a year ago. For the fiscal year 2015, the company expected adjusted income to be in the range of $12.4 to $13.0 billion, adjusted diluted EPS to be in the range of $2.00 to $2.10, net income attributable to company to be in the range of $8.5 billion to $9.4 billion and diluted EPS to be in the range of $1.37 to $1.52. The company expects its tax rate on adjusted income to be approximately 25%.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PFE:SW SFr.29.20 CHF -0.45

PFE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Amgen Inc $152.26 USD -4.11
Gilead Sciences Inc $104.83 USD +0.65
Novartis AG SFr.90.15 CHF -0.85
Roche Holding AG SFr.248.60 CHF -4.10
Sanofi €82.00 EUR -0.26
View Industry Companies

Industry Analysis


Industry Average

Valuation PFE Industry Range
Price/Earnings 22.5x
Price/Sales 4.0x
Price/Book 2.6x
Price/Cash Flow 15.2x
TEV/Sales 2.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PFIZER INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at